A phase I, open label, dose ranging study to evaluate the safety and tolerance of CreaVax-RA in active rheumatoid arthritis patients with usual DMARDs.
Phase of Trial: Phase I
Latest Information Update: 25 Aug 2016
At a glance
- Drugs Dendritic cell vaccine-CreaGene (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 07 Nov 2011 Additional lead trial centre identified as reported by Korean Clinical Trials Register record.
- 13 Sep 2011 New trial record